Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BG9924 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| BG9924 | DRUG | - |
Inclusion Criteria: * Must give written informed consent. If required by local law, candidates must also authorize the release and use of protected health information (PHI). * Male or female subjects aged 18 to 75 years old, inclusive, at the time informed consent is given. * Must have a diagnosis ...
Top 20 of 28 competitors
BG9924 is an investigational small molecule being studied for the treatment of rheumatoid arthritis. It is designed to be used in combination with methotrexate in patients with active disease. The drug is currently in Phase 2 clinical development and is not yet approved by regulatory authorities.
BG9924 is being developed by Biogen Inc., a biotechnology company traded on the NASDAQ under the ticker symbol BIIB. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational drug for rheumatoid arthritis.
BG9924 is in Phase 2 clinical development. A Phase 2 dose-escalating study has been completed, evaluating the drug in combination with methotrexate in patients with active rheumatoid arthritis. The drug remains investigational and has not received regulatory approval.
BG9924 has one completed Phase 2 clinical trial registered as NCT00292422, titled "Dose-Escalating Study of BG9924 in Combination With Methotrexate in Active Rheumatoid Arthritis." The study enrolled 50 participants in the United States and Poland and was a randomized, double-blind trial.
BG9924 is not FDA approved. It is an investigational drug currently in Phase 2 clinical development for rheumatoid arthritis. A Phase 2 clinical trial has been completed, but the drug has not yet received marketing authorization from the FDA or other regulatory agencies.